Second‐line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild‐type KRAS

The goal of the present study was to compare the efficacy of the combination of cetuximab and irinotecan to the combination of oxaliplatin and fluoropyrimidines as second‐line chemotherapy in patients with irinotecan‐refractory and oxaliplatin‐naïve metastatic colorectal cancer (mCRC) harboring wild...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Sci
Hlavní autoři: Hong, Yong Sang, Kim, Hwa Jung, Park, Seong Joon, Kim, Kyu‐Pyo, Lee, Jae‐Lyun, Park, Jin Hong, Kim, Jong Hoon, Lim, Seok‐Byung, Yu, Chang Sik, Kim, Jin Cheon, Baek, Ji Yeon, Kim, Sun Young, Kim, Tae Won
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2013
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7657158/
https://ncbi.nlm.nih.gov/pubmed/23298313
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12098
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky